Publications by authors named "Grethel Miro"
Article Synopsis
- Bamlanivimab and casirivimab/imdevimab are monoclonal antibody treatments that lower COVID-19 viral load and might prevent hospitalizations, but limited data exists comparing their effectiveness.
- A study involving emergency department patients with COVID-19 assessed the efficacy and safety of these treatments by monitoring hospitalizations, symptom improvement, and adverse reactions over 30 days.
- Results showed no significant differences in hospitalization rates or other outcomes between the two treatments, with few adverse events reported.
